ReviewMedical2026
Exploring the Role of Leukocyte Telomere Length and Human Telomerase Reverse Transcriptase MNS16A Variant in Cannabis or Synthetic Cannabinoid Use Disorder.
Pehlivan S.; Nursal A.; Aytac H.; Oyaci Y.; Aytac E.; Pehlivan M. · Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026
Research summary
**Background & Methods**
This cross-sectional comparative study enrolled 228 participants (147 with cannabis or synthetic cannabinoid use disorder [CUD/SCUD] and 81 healthy controls) to investigate associations between the human telomerase reverse transcriptase gene (hTERT)-MNS16A polymorphism and cannabinoid use disorder. Genotyping was performed using polymerase chain reaction (PCR), and leukocyte telomere length (LTL) was measured via real-time PCR with results expressed as relative T/S ratios (telomere length relative to single-copy gene).
**Key Findings**
• Patients with CUD/SCUD demonstrated significantly greater leukocyte telomere shortening compared to controls (p = 0.001), suggesting accelerated cellular aging in this population.
• Among CUD/SCUD patients, those with elevated T/S ratios (>1) exhibited significantly higher prevalence of psychotic symptoms (p = 0.022) and violent behaviors (p = 0.011) compared to those with lower T/S ratios (<1).
• The hTERT-MNS16A L/L genotype was significantly associated with violent behavior in CUD/SCUD patients (p = 0.005), though no significant genotype distribution differences were found between patients and controls overall, indicating the polymorphism does not appear to increase susceptibility to developing CUD/SCUD.
**Dosage & Administration**
Not reported.
**Safety & Adverse Effects**
Not reported. The study examined clinical behavioral manifestations (psychotic symptoms and violent behavior) as outcomes rather than acute adverse effects.
**Evidence Quality**
This study has several limitations affecting evidence quality. The cross-sectional design prevents causal inference regarding telomere shortening and cannabinoid use. The relatively modest sample size (n=228) may limit generalizability. No information is provided regarding cannabis/synthetic cannabinoid dosage, duration of use, or frequency among patients, limiting clinical correlation. The study does not account for potential confounding variables such as age, smoking status, other substance use, or psychiatric comorbidities that could influence telomere length. Publication year (2026) requires verification. Overall, this represents preliminary observational evidence (Level 3-4) suggesting an association between CUD/SCUD and telomere shortening, warranting larger prospective studies with comprehensive phenotyping.
Summary generated by DeepWeed from the published abstract. See the original paper for full methods and results.
Journal
Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology
Ask how this study fits the wider evidence — across 26,000+ papers.
Ask DeepWeed
More recent cannabis research
This page summarises published research for informational purposes only — it isn't medical advice. Always refer to the original publication for full methods, results and limitations.